Brainsway Deep TMS Therapy - for Brain Disorder Treatment

Parkinson's Disease - Double-Blind Placebo Control Safety and Feasibility Study

Sheba Medical Center, Tel-Hashomer, Israel

28 January, 2008

The purpose of this study is to test the effects of low frequency deep Brainsway® rTMS using the novel H-coil on the motor, affective and cognitive deficits in patients with asymmetric Parkinson's disease (PD), to establish its safety in this population and to test effects of maintenance treatments. 

We anticipate that reaching deeper brain layers and larger volume of activation with the H-coil may induce significant therapeutic effects in patients with PD and will pave the way for establishing a novel and effective treatment for this disorder. The study population is 44 patients with asymmetric idiopathic PD, on stable antiparkinsonian therapy, with partial response.

Outcome measures will be taken prior to the treatment (screening visit), and at day 1, 10, 30, 60 and 90. Evaluation will be while subjects are both at "on" and "off".

 Contact: Ester Stein, + (972) 03-530-4931, esther.stein@sheba.health.gov.il

Principal Investigator: Dr. Oren Cohen


© Brainsway Ltd.® 2014 | All rights reserved. Patients Portal · Brainsway Deep TMS · FDA Clearance · Disclaimer · Privacy Policy · Terms of Use